Mode
Home
Conditions Medications Drug Pipeline Weekly Digests
Text Size
Log in / Sign up
Home › Medications › lecanemab

lecanemab

2 published articles · Updated continuously

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Meta-analysis finds trivial cognitive effects of amyloid antibodies in mild Alzheimer's disease
Neurology Meta-analysis
Meta-analysis finds trivial cognitive effects of amyloid antibodies in mild Alzheimer's disease Alzheimer’s Drugs Clear Plaques But Don’t Help Memory
This meta-analysis of 17 randomized trials found amyloid-beta-targeting monoclonal antibodies probably have little to no effect on cognitive…
This review shows that even when Alzheimer’s drugs clear amyloid from the brain, patients don’t see meaningful improvements in memory or dai…
Apr 22, 2026
Lecanemab slowed cognitive decline in ApoE4 non-carriers and heterozygotes with early Alzheimer's disease.
Neurology RCT
Lecanemab slowed cognitive decline in ApoE4 non-carriers and heterozygotes with early Alzheimer's disease. A New Alzheimer's Drug Shows Stronger Promise for Most People at Risk
This Phase 3 subgroup analysis of an RCT evaluated lecanemab in 1,521 individuals with early Alzheimer's disease who were ApoE4 non-carriers…
For the majority of people facing early Alzheimer's, starting this treatment sooner may help preserve more of their daily life for longer.
Apr 10, 2026